General Newsroom Hero 1920x480 (4:1)
Our Work

Latham & Watkins Advises Ra Pharmaceuticals on US$2.1 Billion Acquisition by UCB

October 10, 2019
A bicoastal corporate team advised on the multi-billion dollar biopharmaceutical transaction.

UCB and Ra Pharmaceuticals Inc. (NASDAQ: RARX, Ra Pharma) have announced their entry into a merger agreement pursuant to which UCB will acquire Ra Pharma. Under the terms of the agreement, Ra Pharma shareholders will receive US$48 in cash for each Ra Pharma share at closing, with a total transaction value of approximately US$2.1 billion. The Boards of Directors of both companies have unanimously approved the transaction, which remains subject to approval by Ra Pharma shareholders and to obtaining antitrust clearance and other customary closing conditions. 

Latham & Watkins LLP represents Ra Pharmaceuticals Inc. in the transaction with a corporate deal team led by partners Scott Shean, Daniel Rees, and Peter Handrinos with associates Amro Suboh, Brian Umanoff, Stephanie Isaia, Madison Mapes, and Nicole McNeil. Advice was also provided on tax matters by partner Lisa Watts with associate Anne McGinnis; on benefits and compensation matters by partner Matthew Conway with associate Nikhil Kumar; on intellectual property matters by counsel David Kuiper; on antitrust matters by partner Joshua Holian; on finance matters by partner Wesley Holmes; and on regulatory matters by partner Elizabeth Richards.



    Related Capabilities